# Efficacy Safety Study of Arformoterol/Tiotropium Combination Versus Either Therapy Alone in Chronic Obstructive Pulmonary Disease (COPD)

> **NCT00424528** · PHASE4 · COMPLETED · sponsor: **Sumitomo Pharma America, Inc.** · enrollment: 235 (actual)

## Conditions studied

- Chronic Obstructive Pulmonary Disease
- Bronchitis
- Emphysema

## Interventions

- **DRUG:** Arformoterol Tartrate Inhalation Solution
- **DRUG:** Tiotropium
- **DRUG:** Arformoterol and Tiotropium
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00424528
- **Lead sponsor:** Sumitomo Pharma America, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-12
- **Primary completion:** 2007-10
- **Final completion:** 2007-10
- **Target enrollment:** 235 (ACTUAL)
- **Last updated:** 2012-06-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00424528

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00424528, "Efficacy Safety Study of Arformoterol/Tiotropium Combination Versus Either Therapy Alone in Chronic Obstructive Pulmonary Disease (COPD)". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT00424528. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*